Genenta Science (NASDAQ:GNTA) and SpringWorks Therapeutics (NASDAQ:SWTX) Critical Comparison

Genenta Science (NASDAQ:GNTA) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of current recommendations and price targets for Genenta Science and SpringWorks Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	0	0	1	0	3.00
SpringWorks Therapeutics	0	7	1	0	2.13

Genenta Science presently has a consensus price target of $25.00, indicating a potential upside of 545.16%. SpringWorks Therapeutics has a consensus price target of $52.57, indicating a potential upside of 12.38%. Given Genenta Science’s stronger consensus rating and higher probable upside, equities analysts clearly believe Genenta Science is more favorable than SpringWorks Therapeutics.

Risk & Volatility

Genenta Science has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Institutional & Insider Ownership

15.1% of Genenta Science shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 7.8% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Genenta Science and SpringWorks Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$12.60 million	N/A	N/A
SpringWorks Therapeutics	$219.67 million	16.05	-$325.10 million	($3.41)	-13.72

Genenta Science has higher earnings, but lower revenue than SpringWorks Therapeutics.

Profitability

This table compares Genenta Science and SpringWorks Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
SpringWorks Therapeutics	-134.73%	-46.74%	-41.12%

Summary

Genenta Science beats SpringWorks Therapeutics on 9 of the 10 factors compared between the two stocks.

About Genenta Science

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.